NCT06762132View on ClinicalTrials.gov

A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

CD33 CAR T-cells

Each subject receive CD33 CAR T-cells by intravenous infusion

Trial Locations (1)

310003

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER